The Use of Single Chain Fv As Targeting Agents for Immunoliposomes: an Update on Immunoliposomal Drugs for Cancer Treatment

Overview

Journal Expert Opin Drug Deliv

Publisher Informa Healthcare

Specialty Pharmacology

Date 2010 Mar 25

PMID 20331354

Citations 27

Authors

W W Cheng

T M Allen

Affiliations

Soon will be listed here.

Abstract

Importance Of The Field: Targeted liposomal drugs represent the next evolution of liposomal drug delivery in cancer treatment. In various preclinical cancer models, antibody-targeted PEGylated liposomal drugs have demonstrated superior therapeutic effects over their non-targeted counterparts. Single chain Fv (scFv) has gained popularity in recent years as the targeting agent of choice over traditional targeting agents such as monoclonal antibodies (mAb) and antibody fragments (e.g., Fab').

Areas Covered In This Review: This review is focused mainly on advances in scFv-targeted liposomal drug delivery for the treatment of cancers, based on a survey of the recent literature, and on experiments done in a murine model of human B-lymphoma, using anti-CD19 targeted liposomes targeted with whole mAb, Fab' fragments and scFv fragments.

What The Reader Will Gain: This review examines the recent advances in PEGylated immunoliposomal drug delivery, focusing on scFv fragments as targeting agents, in comparison with Fab' and mAb.

Take Home Message: For clinical development, scFv are potentially preferred targeting agents for PEGylated liposomes over mAb and Fab', owing to factors such as decreased immunogenicity, and pharmacokinetics/biodistribution profiles that are similar to non-targeted PEGylated (Stealth) liposomes.

Citing Articles

The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases.

Okafor N, Omoteso O, Choonara Y Discov Nano. 2025; 20(1):19.

PMID: 39883380 PMC: 11782757. DOI: 10.1186/s11671-024-04170-x.

Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery.

Ho K, Liu Y, Liao T, Liu E, Cheng T Int J Nanomedicine. 2024; 19:10045-10064.

PMID: 39371476 PMC: 11453133. DOI: 10.2147/IJN.S479270.

A Holographic-Type Model in the Description of Polymer-Drug Delivery Processes.

Nica I, Volovat C, Boboc D, Popa O, Ochiuz L, Vasincu D Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675501 PMC: 11053585. DOI: 10.3390/ph17040541.

Photoactive imaging and therapy for colorectal cancer using a CEA-Affimer conjugated Foslip nanoparticle.

Khaled Y, Khot M, Aiyappa-Maudsley R, Maisey T, Pramanik A, Tiernan J Nanoscale. 2024; 16(14):7185-7199.

PMID: 38506227 PMC: 10993305. DOI: 10.1039/d3nr04118b.

Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma.

Schnorenberg M, Hawley K, Thomas-Toth A, Watkins E, Tian Y, Ting J ACS Nano. 2023; 17(23):23374-23390.

PMID: 37688780 PMC: 10722602. DOI: 10.1021/acsnano.3c04112.

References

Shaki-Loewenstein S, Zfania R, Hyland S, Wels W, Benhar I . A universal strategy for stable intracellular antibodies. J Immunol Methods. 2005; 303(1-2):19-39. DOI: 10.1016/j.jim.2005.05.004. View

Pedroso I, Irun M, Machicado C, Sancho J . Four-state equilibrium unfolding of an scFv antibody fragment. Biochemistry. 2002; 41(31):9873-84. DOI: 10.1021/bi025742e. View

Sachetelli S, Beaulac C, Riffon R, Lagace J . Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim Biophys Acta. 1999; 1428(2-3):334-40. DOI: 10.1016/s0304-4165(99)00078-1. View

Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase E, Allen T . Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003; 63(1):86-92. View

Abraham S, McKenzie C, Masin D, Ng R, Harasym T, Mayer L . In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res. 2004; 10(2):728-38. DOI: 10.1158/1078-0432.ccr-1131-03. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Laginha K, Mumbengegwi D, Allen T . Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta. 2005; 1711(1):25-32. DOI: 10.1016/j.bbamem.2005.02.007. View

Thorpe S, Turner C, Heath A, Feavers I, Vatn I, Natvig J . Clonal analysis of a human antimouse antibody (HAMA) response. Scand J Immunol. 2003; 57(1):85-92. DOI: 10.1046/j.1365-3083.2003.01189.x. View

Proba K, Worn A, Honegger A, Pluckthun A . Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol. 1998; 275(2):245-53. DOI: 10.1006/jmbi.1997.1457. View

10.

An F, Drummond D, Wilson S, Kirpotin D, Nishimura S, Broaddus V . Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther. 2008; 7(3):569-78. PMC: 2943512. DOI: 10.1158/1535-7163.MCT-07-2132. View

11.

Cheng W, Allen T . Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release. 2007; 126(1):50-8. DOI: 10.1016/j.jconrel.2007.11.005. View

12.

Romberg B, Metselaar J, Baranyi L, Snel C, Bunger R, Hennink W . Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes. Int J Pharm. 2006; 331(2):186-9. DOI: 10.1016/j.ijpharm.2006.11.018. View

13.

Lopes de Menezes D, Pilarski L, Allen T . In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998; 58(15):3320-30. View

14.

Allen T, Brandeis E, Hansen C, Kao G, Zalipsky S . A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1995; 1237(2):99-108. DOI: 10.1016/0005-2736(95)00085-h. View

15.

Pan X, Lee R . Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int J Pharm. 2007; 336(2):276-83. DOI: 10.1016/j.ijpharm.2006.12.007. View

16.

Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U . Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm. 1999; 181(1):79-93. DOI: 10.1016/s0378-5173(99)00002-2. View

17.

Kong G, Braun R, Dewhirst M . Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001; 61(7):3027-32. View

18.

Glennie M, van de Winkel J . Renaissance of cancer therapeutic antibodies. Drug Discov Today. 2003; 8(11):503-10. DOI: 10.1016/s1359-6446(03)02714-4. View

19.

Bang S, Nagata S, Onda M, Kreitman R, Pastan I . HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res. 2005; 11(4):1545-50. DOI: 10.1158/1078-0432.CCR-04-1939. View

20.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View